Pharma China (www.pharmachinaonline.com) is the most influential English media and source of business intelligence covering the Chinese pharmaceutical sector. Pharma China caters for the growing needs of the international pharmaceutical industry for up-to-date and insightful information and intelligence on China’s burgeoning but increasingly complex healthcare marketplace, and is subscribed by most MNC pharma companies, leading CROs, investment banks, consulting firms active in China as well as relevant industry associations and government agencies.

Note: To view full text of free articles, you need to register as a basic member first and then log in. To view premium articles, you need to subscribe to Pharma China as a premium member. For more information or subscription, please contact info@pharmachinaonline.com. If you wish to unsubscribe from this e-Alert, please reply this e-mail with "Remove" in the subject line.
Editor´s Picks
China: AstraZeneca¡¯s New Engine for Growth and Innovation(10/9/2018 )  (Premium)
Biosimilars and Healthcare Policy: What China Can Learn from the EU and US(10/8/2018 )  (Premium)
Why China Is Going All Out to Invent New, Stronger, Cheaper Drugs(10/8/2018 )  (Premium)
SCMP: Betting Big on Biotech(10/8/2018 )  (Premium)
Industry News
Eisai's NDA for Antiepileptic Drug Perampanel Accepted in China(10/12/2018 )  (Premium)
Mesoblast and Tasly Complete Strategic Cardiovascular Partnership in China(10/12/2018 )  (free)
MEI Pharma and BeiGene Announce Collaboration for ME-401/Zanubrutinib Combination(10/11/2018 )  (Premium)
Daiichi Sankyo Enters Deal with MVP for Distribution of Pain Medicine in China(10/9/2018 )  (Premium)
Beigene Teams up With Springworks to Target Advanced Solid Tumors(10/9/2018 )  (Premium)
Listed Chinese Pharma Cos Reports Positive Performance in H1(10/9/2018 )  (Premium)
Genscript Denies Fake Data Allegations after Shares Plunge(10/8/2018 )  (Premium)
Amyris Enters into Extensive Partnership with Yifan Pharma(10/8/2018 )  (Premium)
Regulatory News
State Council Issues New Document to Reform Licensing Mechanisms(10/11/2018 )  (Premium)
CDE Solicits Comments on Technical Requirements for Manufacturing Site Changes of Oral Solid SR/CR Formulations(10/8/2018 )  (Premium)
NMPA Issues Rules for Communications Related to Drug R&D and Technical Evaluation(10/8/2018 )  (Premium)
General Health
NEJM and CCA Enter Partnership for CVS Research and Training(10/11/2018 )  (Premium)
SMIA Issues Official Notice on Approval of 17 Anticancer Drugs for BMI Reimbursement Listing(10/10/2018 )  (Premium)
China's HIV/AIDS Cases Rise by 14%(10/9/2018 )  (free)
NHC Reports Higher Health Literacy in China(10/9/2018 )  (Premium)
Legal/IPR News
New U.S. Rules on Foreign Investment to Curb Chinese Goldrush in U.S. Biotech(10/10/2018 )  (Premium)
Chinese Prof at MD Anderson Cancer Center under Scrutiny for Spying(10/9/2018 )  (Premium)
Product/R&D News
Innovent to Start US Trials of Anti-CD47 Cancer Drug(10/8/2018 )  (Premium)
Yisheng Biopharma Cleared by NMPA to Proceed with PIKA Rabies Vaccine Clinical Study(10/8/2018 )  (Premium)
CANbridge Submits NDA for NERLYNX (neratinib) in China(10/8/2018 )  (Premium)
© Wicon International Group¡¡Support by: www.heightow.com Home | Site map | Contact Us | Links